Heterogeneity of the tumor immune microenvironment and clinical interventions

作者全名："Jin, Zheng; Zhou, Qin; Cheng, Jia-Nan; Jia, Qingzhu; Zhu, Bo"

作者地址："[Jin, Zheng; Zhou, Qin; Cheng, Jia-Nan; Jia, Qingzhu; Zhu, Bo] Army Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400037, Peoples R China; [Jin, Zheng; Zhou, Qin; Cheng, Jia-Nan; Jia, Qingzhu; Zhu, Bo] Key Lab Tumor Immunotherapy, Chongqing 400037, Peoples R China; [Jin, Zheng] Glorious Med Clin Lab Shanghai Co Ltd, Res Inst, Shanghai 201318, Peoples R China; [Jin, Zheng] Chongqing Med Univ, Inst Life Sci, Chongqing 400016, Peoples R China; [Zhou, Qin] Chongqing Univ Technol, Sch Pharm & Bioengn, Chongqing 400054, Peoples R China"

通信作者："Cheng, JN; Jia, QZ; Zhu, B (通讯作者)，Army Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400037, Peoples R China.; Cheng, JN; Jia, QZ; Zhu, B (通讯作者)，Key Lab Tumor Immunotherapy, Chongqing 400037, Peoples R China."

来源：FRONTIERS OF MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001067339100001

JCR分区：Q2

影响因子：3.9

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Review; Early Access

关键词：tumor immune heterogeneity; clinical intervention; tumor microenvironment

摘要："The tumor immune microenvironment (TIME) is broadly composed of various immune cells, and its heterogeneity is characterized by both immune cells and stromal cells. During the course of tumor formation and progression and anti-tumor treatment, the composition of the TIME becomes heterogeneous. Such immunological heterogeneity is not only present between populations but also exists on temporal and spatial scales. Owing to the existence of TIME, clinical outcomes can differ when a similar treatment strategy is provided to patients. Therefore, a comprehensive assessment of TIME heterogeneity is essential for developing precise and effective therapies. Facilitated by advanced technologies, it is possible to understand the complexity and diversity of the TIME and its influence on therapy responses. In this review, we discuss the potential reasons for TIME heterogeneity and the current approaches used to explore it. We also summarize clinical intervention strategies based on associated mechanisms or targets to control immunological heterogeneity."

基金机构："National Natural Science Foundation of China [82102878, 82073147]; Natural Science Foundation of Chongqing [cstc2021jcyj-msxm3521]; Chongqing PhD scientific project [sl202100000575]"

基金资助正文："The study was supported by the National Natural Science Foundation of China (No. 82102878 to Jia-Nan Cheng and No. 82073147 to Qingzhu Jia), the Natural Science Foundation of Chongqing (No. cstc2021jcyj-msxm3521 to Jia-Nan Cheng), and the Chongqing PhD scientific project (No. sl202100000575 to JiaNan Cheng)."